Objective To evaluate the cardioprotective effects of dexrazoxane (DEX) on acute myelogenous leukemia patients who received anthracycline-containing chemotherapy. Methods A total of 32 acute myelogenous leukemia patients were randomly divided into two groups:the experimental group and the control group.The experimental group of 16 cases treated with EPI plus DEX as adjuvant chemotherapy regimen,and the control group of 16 cases treated with EPI without DEX.All patients received three cycles of adjuvant chemotherapy,compare changes of electrocardiogram、BNP、cTnT and LVEF before and after chemotherapy,and compare the treatment effect between the two groups. Results Brain natriuretic peptide (BNP)before chemotherapy and after three cycles of chemotherapy in the control group was (102.98±5.67)×10-6 ug/ml and (168.46±7.75)×10-6 ug/ml,respectively,with a significant difference between them (p<0.05) .It in the experimental group was (103.02±6.42)×10-6 ug/ml and (112.78±6.69)×10-6 ug/ml,respectively,without a significant difference(P>0.05) .Cardiac troponin T(cTnT) before chemotherapy and after three cycles of chemotherapy in the control group was (12.48±2.46)×10-3ug/ml和(29.68 ±5.68)×10-3ug/ml,respectively,with a significant difference between them(p<0.05) .It in the experimental group was (12.73±2.27)×10-3ug/ml和(14.34±5.12)×10-3ug/ml,respectively,without a significant difference(P>0. 05).The left ventricular ejection fraction (LVEF) before chemotherapy and after three cycles of chemotherapy in the control group was (62.67±6.42)%and (53.39 ±5.57)%,respectively,with a significant difference between them(P<0.05).It in the experimental group was (63.18±5.97)%和(59.15±5.02)%,respectively,without a significant difference (P>0.05) .The experimental group and control group in incidence of abnormal ecg was 12.5%(2/16) and 43.75%(7/16) ,with a significant difference between them(p<0.05).The treatment effect between the experimental group and control group without a significant difference (P>0.05). Conclusion Dexrazoxane has the pertective effect on cardiotoxicity in acute myelogenous leukemia patients who received anthracycline-containing chemotherapy,and does not affect the antitumor efficacy anthracycline-based drugs.%目的：探讨右丙亚胺对接受蒽环类药物化疗的急性非淋巴细胞白血病患者的心肌保护作用。方法32例急性非淋巴细胞白血病患者随机分为实验组及对照组，每组16例。所有患者均采用含蒽环类药物的化疗方案进行治疗，实验组在用含蒽环类药物化疗方案的同时，加用右丙亚胺治疗；对照组仅采用含蒽环类药物化疗方案。化疗3个疗程，观察治疗前后各组患者的心电图异常率，B型脑利钠肽（BNP）、左心室射血分数及心肌肌钙蛋白的定性检测，并评估两组治疗效果。结果对照组患者化疗前后BNP分别为（102.98±5.67）×10-6 ug/ml和（168.46±7.75）×10-6 ug/ml，差异有统计学意义（P<0.05）；实验组患者化疗前后BNP分别为（103.02±6.42）×10-6 ug/ml和（112.78±6.69）×10-6 ug/ml，差异无统计学意义（P>0.05）。对照组患者化疗前后心肌肌钙蛋白T（cTnT）分别为（12.48±2.46）×10-3 ug/ml和（29.68±5.68）×10-3 ug/ml，差异有统计学意义（P<0.05）；实验组患者化疗前后cTnT分别为（12.73±2.27）×10-3 ug/ml和（14.34±5.12）×10-3 ug/ml，差异无统计学意义（P>0.05）。对照组患者化疗前后左室射血分数（LVEF）分别为（62.67±6.42）%和（53.39±5.57）%，差异有统计学意义（P<0.05）；实验组化疗前后LVEF分别为（63.18±5.97）%和（59.15±5.02）%，差异无统计学意义（P>0.05）。实验组与对照组心电图异常发生率分别为12.5%（2/16）和43.75%（7/16），差异有统计学意义（P<0.05）。化疗后两组治疗效果差异无统计学意义（P>0.05）。结论右丙亚胺对使用蒽环类药物化疗的急性非淋巴细胞白血病患者所致的心脏毒性具有保护作用，且不影响蒽环类药物抗肿瘤疗效。
展开▼
